vs
Pacira BioSciences, Inc.（PCRX）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是Pacira BioSciences, Inc.的1.1倍（$217.4M vs $196.9M），Pacira BioSciences, Inc.同比增速更快（5.1% vs 0.5%），Pacira BioSciences, Inc.自由现金流更多（$43.5M vs $36.4M），过去两年Pacira BioSciences, Inc.的营收复合增速更高（8.5% vs 3.0%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
PCRX vs RPD — 直观对比
营收规模更大
RPD
是对方的1.1倍
$196.9M
营收增速更快
PCRX
高出4.6%
0.5%
自由现金流更多
PCRX
多$7.0M
$36.4M
两年增速更快
PCRX
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $196.9M | $217.4M |
| 净利润 | — | $3.1M |
| 毛利率 | 79.5% | 68.9% |
| 营业利润率 | 1.2% | 1.0% |
| 净利率 | — | 1.4% |
| 营收同比 | 5.1% | 0.5% |
| 净利润同比 | — | 44.1% |
| 每股收益（稀释后） | $0.05 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRPD
| Q4 25 | $196.9M | $217.4M | ||
| Q3 25 | $179.5M | $218.0M | ||
| Q2 25 | $181.1M | $214.2M | ||
| Q1 25 | $168.9M | $210.3M | ||
| Q4 24 | $187.3M | $216.3M | ||
| Q3 24 | $168.6M | $214.7M | ||
| Q2 24 | $178.0M | $208.0M | ||
| Q1 24 | $167.1M | $205.1M |
净利润PCRXRPD
| Q4 25 | — | $3.1M | ||
| Q3 25 | $5.4M | $9.8M | ||
| Q2 25 | $-4.8M | $8.3M | ||
| Q1 25 | $4.8M | $2.1M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $-143.5M | $15.4M | ||
| Q2 24 | $18.9M | $6.5M | ||
| Q1 24 | $9.0M | $1.4M |
毛利率PCRXRPD
| Q4 25 | 79.5% | 68.9% | ||
| Q3 25 | 80.9% | 70.2% | ||
| Q2 25 | 77.4% | 70.6% | ||
| Q1 25 | 79.7% | 71.7% | ||
| Q4 24 | 78.7% | 69.5% | ||
| Q3 24 | 76.9% | 70.6% | ||
| Q2 24 | 75.1% | 70.7% | ||
| Q1 24 | 71.6% | 70.3% |
营业利润率PCRXRPD
| Q4 25 | 1.2% | 1.0% | ||
| Q3 25 | 3.5% | 2.7% | ||
| Q2 25 | 4.7% | 1.6% | ||
| Q1 25 | 1.2% | -0.0% | ||
| Q4 24 | 13.2% | 3.4% | ||
| Q3 24 | -82.8% | 6.0% | ||
| Q2 24 | 15.9% | 2.5% | ||
| Q1 24 | 7.9% | 4.7% |
净利率PCRXRPD
| Q4 25 | — | 1.4% | ||
| Q3 25 | 3.0% | 4.5% | ||
| Q2 25 | -2.7% | 3.9% | ||
| Q1 25 | 2.8% | 1.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | -85.1% | 7.2% | ||
| Q2 24 | 10.6% | 3.1% | ||
| Q1 24 | 5.4% | 0.7% |
每股收益（稀释后）PCRXRPD
| Q4 25 | $0.05 | $0.05 | ||
| Q3 25 | $0.12 | $0.15 | ||
| Q2 25 | $-0.11 | $0.13 | ||
| Q1 25 | $0.10 | $0.03 | ||
| Q4 24 | $0.38 | $0.08 | ||
| Q3 24 | $-3.11 | $0.21 | ||
| Q2 24 | $0.39 | $0.09 | ||
| Q1 24 | $0.19 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.4M | $474.7M |
| 总债务越低越好 | $372.2M | — |
| 股东权益账面价值 | $693.1M | $154.7M |
| 总资产 | $1.3B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.54× | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXRPD
| Q4 25 | $238.4M | $474.7M | ||
| Q3 25 | $246.3M | $407.1M | ||
| Q2 25 | $445.9M | $511.7M | ||
| Q1 25 | $493.6M | $493.5M | ||
| Q4 24 | $484.6M | $521.7M | ||
| Q3 24 | $453.8M | $443.7M | ||
| Q2 24 | $404.2M | $442.6M | ||
| Q1 24 | $325.9M | $411.7M |
总债务PCRXRPD
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PCRXRPD
| Q4 25 | $693.1M | $154.7M | ||
| Q3 25 | $727.2M | $127.2M | ||
| Q2 25 | $757.8M | $90.4M | ||
| Q1 25 | $798.5M | $52.7M | ||
| Q4 24 | $778.3M | $17.7M | ||
| Q3 24 | $749.6M | $-5.1M | ||
| Q2 24 | $879.3M | $-52.6M | ||
| Q1 24 | $892.2M | $-86.4M |
总资产PCRXRPD
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.5B | $1.6B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.6B | $1.5B | ||
| Q1 24 | $1.6B | $1.5B |
负债/权益比PCRXRPD
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $43.7M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $43.5M | $36.4M |
| 自由现金流率自由现金流/营收 | 22.1% | 16.8% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 12.01× |
| 过去12个月自由现金流最近4个季度 | $136.7M | $146.2M |
8季度趋势，按日历期对齐
经营现金流PCRXRPD
| Q4 25 | $43.7M | $37.6M | ||
| Q3 25 | $60.8M | $39.0M | ||
| Q2 25 | $12.0M | $47.5M | ||
| Q1 25 | $35.5M | $29.8M | ||
| Q4 24 | $33.1M | $63.8M | ||
| Q3 24 | $53.9M | $44.0M | ||
| Q2 24 | $53.2M | $32.9M | ||
| Q1 24 | $49.1M | $31.1M |
自由现金流PCRXRPD
| Q4 25 | $43.5M | $36.4M | ||
| Q3 25 | $57.0M | $34.8M | ||
| Q2 25 | $9.3M | $46.6M | ||
| Q1 25 | $26.9M | $28.4M | ||
| Q4 24 | $31.0M | $62.6M | ||
| Q3 24 | $49.8M | $42.6M | ||
| Q2 24 | $51.6M | $32.6M | ||
| Q1 24 | $46.3M | $30.4M |
自由现金流率PCRXRPD
| Q4 25 | 22.1% | 16.8% | ||
| Q3 25 | 31.7% | 16.0% | ||
| Q2 25 | 5.1% | 21.8% | ||
| Q1 25 | 15.9% | 13.5% | ||
| Q4 24 | 16.6% | 28.9% | ||
| Q3 24 | 29.6% | 19.9% | ||
| Q2 24 | 29.0% | 15.7% | ||
| Q1 24 | 27.7% | 14.8% |
资本支出强度PCRXRPD
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 2.2% | 1.9% | ||
| Q2 25 | 1.5% | 0.4% | ||
| Q1 25 | 5.1% | 0.6% | ||
| Q4 24 | 1.1% | 0.5% | ||
| Q3 24 | 2.4% | 0.6% | ||
| Q2 24 | 0.9% | 0.1% | ||
| Q1 24 | 1.7% | 0.3% |
现金转化率PCRXRPD
| Q4 25 | — | 12.01× | ||
| Q3 25 | 11.20× | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | 7.37× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | 2.82× | 5.03× | ||
| Q1 24 | 5.47× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
